Israel's Compugen Q2 revenue more than doubles, net loss narrows

Compugen

03/08/2026 12:08

Overview
Israel cancer immunotherapy firm's Q2 revenue more than doubled yr/yr on Gilead license payments
Q2 net loss narrowed slightly from prior year
Company expects cash runway to fund operations into 2029

Outlook
Company says cash runway expected to fund operations into 2029
Partnered clinical trials with AstraZeneca and Gilead continue to progress as planned

Result Drivers
GILEAD LICENSE PAYMENTS - Q2 revenue reflected recognition of upfront and milestone payments from Gilead license agreement
INCREASED R&D SPENDING - R&D expenses rose due to ongoing clinical trial activities

Company press release: ID:nPn6SdYFVa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$2.60 mln
 
Q2 Loss Per Share
 
$0.07
 
Q2 Gross Loss
 
$92,000
 
Q2 Operating Expenses
 
$8.75 mln
 

Reuters Recommended Reads
July 31 - Moderna beats quarterly revenue estimates ahead of key US flu vaccine decision
Aug 3 - BioNTech says Sobi's Oelkers will replace Sahin as CEO
July 31 - Tenax Therapeutics Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)